22 suspended. 22 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Suspended 22 |
| Phase 2 | 6 | Suspended 6 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-06-05 |
| Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 33 | 2024-05-24 | 2026-10-15 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy - Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Suspended | Myeloid Therapeutics | 40 | 2021-12-15 | 2023-11-13 |
| A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer Gamitrinib - Lymphoma, Advanced Solid Tumor | Phase 1 | Suspended | Fox Chase Cancer Center | 42 | 2021-11-05 | 2026-09-21 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
| Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) IMM0306 - B-cell Non-Hodgkin's Lymphoma | Phase 1 | Suspended | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 90 | 2021-01-15 | 2022-09-26 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies SHR-1603 - Physiological Effects of Drugs, Neoplasms by Histologic Type | Phase 1 | Suspended | Jiangsu HengRui Medicine Co., Ltd. | 128 | 2018-11-13 | 2021-03-22 |
| Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas Brentuximab Vedotin, BeEAM Regimen - Lymphoma | Phase 1 / Phase 2 | Suspended | Insel Gruppe AG, University Hospital Bern | 20 | 2018-09-01 | 2025-03-30 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Fludarabine, Laboratory Biomarker Analysis, Melphalan - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission | Phase 1 | Suspended | City of Hope Medical Center | 36 | 2018-07-06 | 2026-09-28 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) P1446A-05 - Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Suspended | Piramal Enterprises Limited | 36 | 2014-06-01 | 2014-09-03 |
Showing 20 of 22. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myeloid, Acute (5) · Lymphoma (5) · Immunoblastic Lymphadenopathy (4) · Lymphoma, T-Cell, Peripheral (4) · Hematologic Neoplasms (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Large-Cell, Anaplastic (3) · Lymphoma, T-Cell (3) · Lymphoma, T-Cell, Cutaneous (3) · Mycosis Fungoides (3) · Myelodysplastic Syndromes (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Enteropathy-Associated T-Cell Lymphoma (2)
Hemic and Lymphatic Diseases (22) · Neoplasms (22) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Lymphoproliferative Disorders (21) · Neoplasms by Histologic Type (21) · Lymphoma, Non-Hodgkin (12) · Hematologic Diseases (11) · Lymphoma (11) · Leukemia, Lymphoid (10) · Leukemia (9) · Leukemia, Myeloid (5) · Lymphoma, B-Cell (5) · Lymphadenopathy (4)
Cyclophosphamide (5) · fludarabine (5) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Melphalan (3) · Brentuximab Vedotin (2) · Leukapheresis (2) · Specimen Handling (2) · Tacrolimus (2) · fludarabine phosphate (2) · Antibodies, Monoclonal (1) · CT-P10 (1) · Cetuximab (1) · Doxorubicin (1) · Drug Therapy (1)
City of Hope Medical Center (3) · Chongqing Precision Biotech Co., Ltd (1) · David Wald (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1) · Insel Gruppe AG, University Hospital Bern (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Masonic Cancer Center, University of Minnesota (1) · MedImmune LLC (1) · Myeloid Therapeutics (1) · National Cancer Institute (NCI) (1) · National University Health System, Singapore (1) · Northwestern University (1) · Piramal Enterprises Limited (1)
United States (16) · China (4) · Singapore (2) · Japan (1) · Switzerland (1)
Alan S. Wayne, MD (1) · Alexandre V. Hirayama, MD (1) · Amandeep Salhotra (1) · Benjamin Tomlinson, MD (1) · Cheng Huang, MD (1) · Dario Campana (1) · Donglai Lv, MD (1) · Dr Alexey V Danilov, MD, PhD (1) · Dr Jennifer R Brown, MD, PhD (1) · Geoffrey Uy, M.D. (1) · Hongtao Liu (1) · Ibrahim Aldoss (1) · Lauren Shea, M.D. (1) · Michele Gerber, MD, MPH (1) · Monzr Al Malki (1)
PMID 28054442, PMID 35129069, PMID 38022532, PMID 40706069, PMID 41117344
P30CA033572 (2), P30CA014599 (1), P30CA060553 (1), R01CA225913 (1)